Detalhe da pesquisa
1.
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
J Med Genet
; 2023 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37940383
2.
An expert consensus on the recommendations for the use of biomarkers in Fabry disease.
Mol Genet Metab
; 139(2): 107585, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37207471
3.
Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry.
Mol Genet Metab
; 138(2): 106967, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36709533
4.
Long-term effectiveness of enzyme replacement therapy in Fabry disease with the p.Arg227Ter variant: Fabry disease in Ostrobothnia (FAST) study.
Am J Med Genet A
; 191(7): 1858-1869, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37078610
5.
European expert consensus statement on therapeutic goals in Fabry disease.
Mol Genet Metab
; 124(3): 189-203, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30017653
6.
Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis.
PLoS Med
; 14(9): e1002389, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28926573
7.
Improved control of blood pressure and albuminuria among patients with type-2 diabetes in Finnish open care.
Blood Press
; 26(2): 67-73, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27310566
8.
Renal involvement in Fabry disease.
Nephrol Dial Transplant
; 34(9): 1435-1437, 2019 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30690583
9.
Hemodynamic Bedside Monitoring Instrument with Pressure and Optical Sensors: Validation and Modality Comparison.
Adv Sci (Weinh)
; : e2307718, 2024 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38647263
10.
Screening and management of hypertensive patients with chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. A pilot survey based on questionnaire.
J Hypertens
; 2024 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38747416
11.
Analysis of left ventricular mass in untreated men and in men treated with agalsidase-ß: data from the Fabry Registry.
Genet Med
; 15(12): 958-65, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23703683
12.
Diffusion tensor imaging and brain volumetry in Fabry disease patients.
Neuroradiology
; 55(5): 551-8, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23292181
13.
Chronic kidney disease stage is associated with the number of risk factors in type 2 diabetes patients (STages Of NEphropathy in type 2 diabetes and Heart Failure - STONE HF).
Prim Care Diabetes
; 17(6): 632-638, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37891057
14.
Development and clinical validation of a miniaturized finger probe for bedside hemodynamic monitoring.
iScience
; 26(11): 108295, 2023 Nov 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38026187
15.
Late-onset and classic phenotypes of Fabry disease in males with the GLA-Thr410Ala mutation.
Open Heart
; 10(1)2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36927868
16.
Assessment of cardiovascular risk in primary health care.
Scand J Prim Health Care
; 30(2): 101-6, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22643155
17.
[Fabry disease]. / Fabryn tauti.
Duodecim
; 128(7): 729-39, 2012.
Artigo
em Fi
| MEDLINE | ID: mdl-22612023
18.
Pulmonary manifestations and the effectiveness of enzyme replacement therapy in Fabry Disease with the p. Arg227Ter (p.R227*) mutation.
Mol Genet Genomic Med
; 10(5): e1915, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35246967
19.
Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan.
J Clin Hypertens (Greenwich)
; 24(7): 804-813, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35686330
20.
The majority of type 2 diabetic patients in Finnish primary care are at very high risk of cardiovascular events: A cross-sectional chart review study (STONE HF).
Prim Care Diabetes
; 16(1): 135-141, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34972659